Podcasts about scientific director

Vassy Kapelos is joined by Yoshua Bengio, President & Scientific Director, LawZero and Full Professor at Université de Montréal, and Founder and Scientific Advisor of Mila – Quebec AI Institute, about this new initiative and its significance in AI. On today's show: Karen Hogan, Auditor General, on the details of her latest reports John Bolton, Former National Security Adviser to US President Donald Trump and Ambassador to the United Nations under President George W. Bush, on the latest developments in the LA protests and the federal response The Explainer: Ryan Manucha, Research Fellow, C.D. Howe Institute and Author, Booze, Cigarettes, and Constitutional Dust-Ups: Canada's Quest for Interprovincial Free Trade, answers this question — what barriers to interprovincial trade exist right now? How much will free internal trade really impact the economy? The Daily Debrief Panel with Supriya Dwivedi, Former Senior Adviser to Prime Minister Justin Trudeau; Jeff Rutledge, Vice President, McMillian Vantage; Stephanie Levitz, senior reporter in The Globe and Mail's Ottawa bureau

Dev Mittar, Ph.D., Scientific Director of the ASM Health Scientific Unit discusses the use of metagenomic next generation sequencing to develop agnostic diagnostic technology, giving scientists and clinicians alike, a tool to diagnose any infectious disease with one single test. He also discusses how the ASM Health Unit is empowering scientists and leveraging microbial science innovations to address critical global health challenges and improve lives worldwide. Ashley's Biggest Takeaways The Division of Research, Innovation and Ventures is a small entrepreneurial arm of BARDA that takes on early-stage projects with high potential of turning into medical countermeasures. Prior to his role as Scientific Director for ASM Health, Mittar worked as a health scientist and program officer at DRIVe, where he focused on advancing high-impact science. He is particularly passionate about his work to develop agnostic diagnostics—a single test that uses metagenomic next generation sequencing to identify any pathogen from 1 clinical sample. Mittar discusses applications for this technology in surveillance (pandemic preparedness), variant detection, AMR and clinical settings (diagnosing complicated infections where etiology is not clearly defined). He also shares how a recent bout with illness emphasized the value and potential of this technology to save money, time, pain and suffering of the patient. Agnostic diagnostics can also help prevent the overuse/misuse of antibiotics, which are key factors in the spread of antimicrobial resistance. Furthermore, when this technology is coupled with the use of metatranscriptomics, it can provide information about the patient's immune profile that can be helpful in developing personalized treatment strategies, as opposed to a one-size-fits-all approach. ASM is organizing around 3 scientific units, ASM Health, ASM Mechanism Discovery and ASM Applied and Environmental Microbiology. These units will empower researchers and scientists to use science make a difference in the world and provide a forum for them to come together to shape the future of the field. Links for This Episode Learn More About ASM's Scientific Units. Join the Conversation on ASM Connect, our online community platform. Browse Volunteer Opportunities. Become an ASM Member. Register for ASM Microbe 2025.

Dr. Jacqueline Barry is the Chief Clinical Officer at Cell and Gene Therapy Catapult, Dr. Kapil Bharti is a Senior Investigator at the National Eye Institute at the National Institutes of Health, and Dr. Jack Mosher is the Scientific Director at the International Society for Stem Cell Research (ISSCR). They discuss their work on the ISSCR's Best Practices for the Development of Pluripotent Stem Cell-Derived Cellular Therapies. They talk about the need for consistency and rigor in cell therapy development, and how the document can be navigated and applied across jurisdictions.

What are we sleeping less and less? What are the benefits of getting a good nights sleep and the risks if we consistently don't? How is sleep linked to memory, cognitive performance, blood sugar regulation & stress hormones? How is young people's development affected by sleep?In this episode we have the surprising data on the science of sleep to get up to date on; so, why there's a sleep deprivation epidemic; how sleep works and what it's required for; dreams; and importance of sleep for learning and for immunity. We're also going to discuss the wide range of serious health issues that arise with even a small sleep deficit, and the vast benefits of getting sleep right; and the lifestyle tips we need to consistently get the sleep we need. And of course, sleep and mental health, and the importance of sleep for development in young people.Gratefully our guest today is a psychologist and neuroscientist that specialises in sleep, mental health and dream research, particularly in young people. She's the Scientific Director of Psychology at the University of St. Thomas, Minnesota, Roxanne Prichard! She's the author of over 40 highly citied scientific papers, and her TEDx talk “Addressing our Childrens Sleep Debt” was featured in the lecture series: Transforming Education. She's quoted regularly in the press, inlcuding the New York Times, Wall Street Journal, Teen Vogue, and USA Today.What we discussed:00:00 Intro.05:00 The Sleep deprivation epidemic.07:15 Shaking off prejudice about resting being laziness. 08:31 Glymphatic system for toxin removal.10:00 Synaptic plasticity: Learning & unlearning.11:10 Learning & memory require sleep.14:00 The hippocampus processes memory during sleep.15:00 Late night cramming for exams blocks learning.15:50 Lack of sleep appears to the body as a threat out in the world.17:40 Blood sugar regulation is affected by sleep.18:00 “Sleep! Like diet and exercise only easier!”19:10 Immunity and sleep deprivation.21:00 Cancer & regularity of circadian rhythms.22:00 Evolution, daylight, circadian rhythms & learning.23:45 Sleep delay of morning stress hormones in teens. 26:15 Light Vs Deep ‘Slow Wave' Vs REM sleep.30:00 REM Sleep explained. 33:00 Dreams: The top theories.36:30 The electrical nature of sleep & brain waves.40:00 Alpha Waves and biofeedback for insomnia.42:00 Insomnia & the health risks of sleep deprivation.46:00 Sleep is within our control.47:15 The inflammation link with sleep.49:30 The mental health risks of sleep deprivation. 50:00 Catastrophising and attention deficit.50:45 College students mental health & sleep as a crucial marker.57:30 Persausive technology, screens & sleep.01:02:30 How much sleep do we need? 01:04:25 Avoid external stimulants & go to low light.01:06:00 Avoid internal stimulants like caffeine and alcohol. 01:07:40 Sleep and wake at regular times every day.01:08:40 Core temperature dropping signals sleep.01:10:00 Roxanne's campaign points.01:12:00 The shame around rest. References: Ya Chai at al, ‘Two nights of recovery sleep restores hippocampal connectivity but not episodic memory after total sleep deprivation' paper.https://www.nature.com/articles/s41598-020-65086-xN.I.H. article, 'Sleep on it - How snoozing strengthens memories' (40% drop in learning after sleep deprivation)https://newsinhealth.nih.gov/2013/04/sleep-itU. Chicago Medicine article, 'New study helps explain the link between sleep loss and diabetes'.Trisha Hershey, ‘the Nap' Bishop. - “Rest is Resistance” book.

Guests:Dr Lorina NaciDr Andrew Godfrey, Medical & Scientific Director of the Irish Blood Transfusion Service

This week, we interview Dr. Cristofanilli, a globally recognised expert in inflammatory breast cancer research and precision medicine. With decades of clinical experience and groundbreaking contributions to translational research, he has transformed the way we approach metastatic breast cancer, leading advances in liquid biopsy, molecular profiling, and targeted therapies.Dr Cristofanilli serves as the Director of Breast Medical Oncology, Associated Director of Precision Oncology at the Meyer Cancer Centre, and co-leader of the MCC Breast Cancer Disease Management team, in addition to being the Scientific Director of the Englander Institute of Precision Medicine.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This week, we're taking you behind the scenes of IVF laboratories with Dr. Melanie Walls, Scientific Director at Concept Fertility Centre. With over 18 years of expertise in IVF laboratories and a unique perspective as both a scientist and former IVF patient, Dr. Walls offers rare insight into one of the most crucial yet least discussed aspects of fertility treatment: identification and traceability. Dr. Walls breaks down the sophisticated systems that ensure your eggs, sperm, and embryos are protected throughout your fertility journey. She explains how electronic witnessing works, the evolution of lab safeguards, and the rigorous regulations Australian fertility labs must follow to maintain the highest standards of care. Whether you're just beginning treatment or deep in your fertility journey, this conversation will give you valuable knowledge about the laboratory processes happening behind the scenes and practical advice for being proactive about your own identification during treatment.This episode is proudly supported by Concept Fertility Centre

What happens when we flip the urban planning script — putting people, not cars, at the heart of our cities and regions? In this 15-minute episode, Professor Carlos Moreno - creator of the “15-minute city” and now a leading voice behind the “30-minute region” - joins the OECD's Soo-Jin Kim to explore how we can build more inclusive, connected and resilient places. From the sidewalks of Paris to rural areas reimagining public services, Carlos shares a bold vision of proximity, empowerment, and local opportunity. Tune in to hear how the future of urban and regional development might be just around the corner — literally. Host: Shayne MacLachlan, Public Affairs and Communications Manager at the OECD Centre for Entrepreneurship, SMEs, Regions and Cities Guests: Carlos Moreno is a Franco-Colombian researcher and Professor at the University of Paris 1 Panthéon-Sorbonne, internationally recognised for developing the 15-minute city concept. He is currently expanding his work through the “30-minute region,” a model designed to bring proximity and accessibility to entire territories beyond urban centres. Carlos serves as Scientific Director of the ETI Chair (“Entrepreneurship – Territory – Innovation”) and advises cities and international organisations on urban innovation and sustainable planning. Soo-Jin Kim is Head of the Urban Policies and Reviews Unit at the OECD Centre for Entrepreneurship, SMEs, Regions and Cities. Her work focuses on helping national and local governments shape more sustainable, inclusive, and resilient cities. She leads cross-country reviews, develops policy guidance, and brings international perspectives to urban development challenges. To learn more about policy area: https://www.oecd.org/en/topics/urban-development.html To learn more about the OECD, our global reach, and how to join us, go to https://www.oecd.org/en/about.html To keep up with latest at the OECD, visit https://www.oecd.org/ Get the latest OECD content delivered directly to your inbox! Subscribe to our newsletters: https://www.oecd.org/en/about/newsletters.html

Overly complex medical information creates a barrier to effective patient care. In this episode, guest host Steve Palmisano, Executive Vice President of Publication Services at The Lockwood Group, leads a discussion with Danielle Grospitch, Scientific Director at The Lockwood Group, and Professor Cynthia Baur, Director of the Horowitz Center for Health Literacy. Together, they examine the challenges patients face when trying to understand medical content and highlight the power of plain language summaries in making that information more accessible.To join ISMPP, visit our website at https://www.ismpp.org/

We've been using red light therapy and laser therapy for well over 20 years it's one of my all-time favorite modalities for healing. In this episode we have Genevieve Newton, DC, PhD with specialization in research of red light therapy. She knows hers stuff. Genevieve is the Scientific Director for Fringe Heals.  My recommnended red light therapy company.  If you've ever wanted to learn more about red light therapy and clear the clutter on what's legit and what's not this is your opportunity. And you get to learn about the products I recommend for all of my patients and use in my clinic. You can visit Fringe here and use my special code 'STOPCHASINGPAIN' to save on all products. Enjoy! LINK: FRINGE HEALS  

Gugs Mhlungu speaks to Scientific Director of the HIV Pathogenesis Programme and a Professor in HIV/TB Research at the University of KwaZulu-Natal, Prof Thumbi Ndung’u on what to make of their groundbreaking study which aims to reduce reliance on ART for HIV patients. Professor Thumbi Ndung'u is the Scientific Director of the HIV Pathogenesis Programme and a Professor in HIV/TB Research at the University of KwaZulu-Natal. He is the Director for Basic and Translational Science at the Africa Health Research Institute (AHRI), a Professor of Infectious Diseases at University College London. He is the Programme Director of the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a research and capacity building initiative. See omnystudio.com/listener for privacy information.

Want healthy skin? It starts with the right facial cleanser. Join Dr. Sandy Skotnicki, Marlo Sutton, and Dr. Elodie Valin, Scientific Director at Bioderma, as they dive into cleansing, micellar water, and how traditional soaps impact your skin barrier.Welcome to Skin to It, the podcast where dermatologist Dr. Sandy Skotnicki and beauty enthusiast Marlo Sutton dive into everything you need to know about healthy skin. In this episode, we break down the history of cleansing, the evolution of gentle cleansers, and the game-changing innovation of Bioderma's micellar cleanser.For today's hot topic, we're delving into the science behind cleansers. Dr. Sandy Skotnicki and Marlo Sutton are joined by Dr. Elodie Valin, a chemical engineer and Bioderma's Scientific Director, to discuss the history and innovation behind facial cleansers and micellar water.What You'll Learn in This Episode:•The history of cleansing, from soap discovery to modern innovations•Why traditional soaps and harsh soaps can harm skin health• How Bioderma micellar cleanser changed the way we think about cleansing• The role of hydrating cleansers and gentle cleansers in skin barrier repair• Common myths about micellar water, including whether it leaves detergent residueEpisode Key Points• The origins of facial cleansers and their effect on the skin microbiome• Why traditional soaps can damage skin and how non-stripping cleansers help• The transition from harsh soaps to dermatologist-recommended cleansers• How micellar cleansers work and why Bioderma's micellar water stands out• How to find the best cleanser for sensitive skinDr. Valin takes us behind the scenes of Bioderma's micellar water, explaining its creation, formulation, and benefits. She also debunks common cleansing myths, including whether micellar water leaves detergent residues on the skin.Whether you're a skincare podcast listener, following beauty trends 2025, or searching for the best skincare podcast, this episode is a must-listen.Listeners will gain a full understanding of cleansers, their history, and why Bioderma's micellar cleanser has become a global favorite.Tune in now and transform your skincare routine.

How can we improve outcomes for cancer patients undergoing surgery? With Immunotherapy! In this episode we discuss perioperative immunotherapy with Dr. Rebecca Auer, a Surgeon-Scientist and the CEO & Scientific Director at the Ottawa Hospital Research Institute. She discusses how her background in surgery and interest in research led her to explore how we can enhance the immune system after surgical removal of cancers to prevent relapse.More information about the clinical trial using a blood thinner to boost the immune response after colon cancer removal: News articleMedical Journal publication--Interested in learning more about immunotherapy? Check out our other episodes and give us a follow on instagram @wthisimmunotherapy and twitter @WTHisImmunoT! And check out our website ⁠wthisimmunotherapy.com⁠. Or feel free to reach out to us at ⁠wthisimmunotherapy@gmail.com⁠ if you have any questions or any ideas for episodes!--Creators & Producers: Gillian Savage, Grace Bernard, and Dr. Pauline Loos Podcast Logo is designed by Mia Portelance Music is by Lara Antebi (⁠https://laraantebi.bandcamp.com/⁠)

The Diabetes Research Institute (DRI) is focused on curing and preventing diabetes. We're checking in to see what's on their radar. Safer islet cell Transplant Options Without Harsh Drugs, smarter devices to protect islets and what they call Quantum Leap projects. I'm talking with Dr. Matthias von Herrath, Scientific Director of DRI and Michael Burton, CEO of Diabetes Research Institute Foundation More about DRI here More about the DRI Foundation here  This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Timeline: Get 10% off Mitopure, clinically proven to boost mitophagy.  Go to timeline.com/vanessa. In this insightful and practical episode, Vanessa sits down with Dr. Latt Mansor—metabolism researcher and Scientific Director at Ketone-IQ—to talk about what it really takes to shed the last 20 pounds of body fat. Dr. Mansor shares his current fat loss journey, including how he's incorporating strategic carbs to break through a plateau after already making incredible progress. Together, they explore the science behind using ketones for fat loss, and debate the merits of strategic carbs vs. high-protein keto—which is the exact approach Vanessa used to achieve her own transformation. This episode brings a perfect blend of real-world experience, nuanced science, and actionable tools to help you navigate the final stretch of fat loss or simply optimize your metabolic health.

Send us a textDr. Dimitris Tsoukalas MD, PhD is a Board-Certified Family Physician, the Scientific Director of the Metabolomic Medicine® Medical Group, President of European Institute of Molecular Medicine, and an Associate Member of the World Academy of Sciences.Dr. Dimitris Tsoukalas is a medical doctor and scientific director of Metabolomic Medicine® medical group, with clinics in Athens Greece and , Milan Italy. He is a pioneer in the prevention and treatment of autoimmune and chronic conditions such as Hashimoto's thyroiditis, rheumatoid arthritis, diabetes, systemic lupus erythematosus, multiple sclerosis, psoriasis, Crohn's disease, and ulcerative colitis, using Metabolomic Analysis®.Metabolomic Analysis® detects deficiencies in micronutrients and the metabolic causes of autoimmune and chronic diseases. He is also the author of the best-selling book How to Live 150 Years in Health.He has published more than 50 scientific studies and is a keynote speaker at international medical conferences for the detection of metabolic disorders and micronutrient deficiencies related to preventing and treating autoimmune and chronic diseases.Find Dr. Tsoukalas at-https://www.drtsoukalas.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

As of February 2025, the Generation Study has recruited over 3,000 participants. In this episode of Behind the Genes, we explore what we have learnt so far from running the study and how it continues to evolve in response to emerging challenges. The conversation delves into key lessons from early recruitment, the challenges of ensuring diverse representation, and the ethical considerations surrounding the storage of genomic data. Our guests discuss how ongoing dialogue with communities is helping to refine recruitment strategies, improve equity in access, and enhance the diversity of genomic data.  Our host Vivienne Parry, Head of Public Engagement at Genomics England, is joined by Alice Tuff-Lacey, Program Director for the Generation Study; Dalia Kasperaviciute, Scientific Director for Human Genomics at Genomics England; and Kerry Leeson Bevers, CEO of Alström Syndrome UK. For more information on the study, visit the Generation Study website, or see below for some of our top blogs and podcasts on the topic: Podcast: What do parents want to know about the Generation Study? Podcast: How has design research shaped the Generation Study? Blog: What is the Generation Study? "We always have to remember, don't we, that if people say no to these things, it's not a failure to on our part, or a failure on their part. It's just something they've thought about and they don't want to do, and for all sorts of different reasons. And the other reflection I have about different communities is the ‘different' bit, is that what approach works for one community may not work for another, and I think that that's something that's going to have to evolve over length of the study, is finding the things that are the right way, the most helpful way to approach people." You can download the transcript, or read it below.   Vivienne: Hello and welcome to Behind the Genes.    Alice: “And this is quite an exciting shift in how we use whole genome sequencing, because what we are talking about is using it in a much more preventative way. Traditionally, where we've been using it is diagnostically where we know someone is sick and they've got symptoms of a rare condition, and we're looking to see what they might have. What we're actually talking about is screening babies from birth using their genome, to see if they are at risk of a particular condition, and what this means is this raising quite a lot of complex ethical, operational, and scientific and clinical questions.”    Vivienne: My name's Vivienne Parry, and I'm Head of Public Engagement here at Genomics England, and I'm your host on this episode of Behind the Genes.      Now, if you are a fan of this podcast, and of course you're a fan of this podcast, you may have already heard us talking about the Generation Study, the very exciting Genomics England research project which aims to screen 100,000 newborn babies for over 200 genetic conditions using whole genome sequencing.      Well, we've got more on the study for you now. What we're doing to make it both accessible and equitable for all parents-to-be, and our plans to ensure that we continue to listen to parents, and perhaps in future, the babies as they grow up. We'll chat, too, about emerging challenges and how we might deal with them.    I'm joined in our studio by Alice Tuff-Lacey, the Programme Director for the Generation Study, and Dalia Kasperaviciute, Scientific Director for Human Genomics, both from Genomics England, and we're delighted to welcome Kerry Leeson-Bevers, Chief Executive of Alström Syndrome UK. And I'm just going to quickly ask Kerry, just tell us about Alström Syndrome and how you're involved.    Kerry: Yes, so Alström Syndrome is an ultra-rare genetic condition. My son has the condition and that's how I got involved. So, the charity has been around now since 1998, so quite a well-established charity, but as part of our work we developed Breaking Down Barriers, which is a network of organisations working to improving engagement and involvement from diverse, marginalised and under-served communities as well.    Vivienne: And you wear another hat as well?  Kerry: I do. So, I'm also a member of the research team working on the process and impact evaluation for the Generation Study. So, I'm Chair of the Patient and Public Involvement and Engagement Advisory Group there.    Vivienne: Well, the multiply hatted Kerry, we're delighted to welcome you. Thank you so much for being with us.      So, first of all, let's just have a sense from Alice Tuff-Lacey about this project. In a nutshell, what's it all about, Alice?  Alice: Thanks Viv. So, I think in the last few years we've seen some really big advances in the diagnoses of rare diseases through things the Genomic Medicine Service. But we know it takes about 5 years often to diagnose most of these rare conditions. What we also know is that there are several hundred of them that are treatable, and actually there can be massive benefits to the child's health from diagnosing and treating them earlier. I think a really good example of this which is often talked about is spinal muscular atrophy, which is a particular condition where there is a genetic treatment available and there is a really big difference in families from those babies where the condition was identified later on, versus their brothers and sisters where they were identified early because they knew there was a sibling that had it and they were given that treatment.     What we think there is a huge potential opportunity to identify these children from their genome before they get ill, and this is quite an exciting shift in how we use whole genome sequencing, because what we are talking about is using it in a much more preventative way.  But this is a really different approach to how we've been using it so far, because traditionally where we have been using it is diagnostically where we know someone is sick and they've got symptoms of a rare condition and we are looking to see what they might have, what we are actually talking about is screening babies from birth using their genome to see if they are at risk of a particular condition. And what this means is, this raises quite a lot of complex ethical, operational and scientific and clinical questions.      So the aim of the Generation Study is really to understand if we can and should use whole genome sequencing in this way to screen for rare conditions in newborn babies. We've been funded by the Department of Health and Social Care to do this over the following years, and the way we'll be doing this is by a national study across a network of trusts in England where we are aiming to recruit about 100,000 babies and screen them for rare treatable conditions that we know present in childhood. And really the aim of this is to understand if this will work and how it will work, and to generate the evidence to allow the NHS and the National Screening Committee to decide if this could become a clinical service, and that's very much the primary goal of the study.      Beyond that, however, there are some other aims of the study, and we also consent mothers to ask permission to retain their genomic data and to link it to the baby's clinical data over their childhood, and we'll be providing access to this to researchers in the de-identified way in our trusted research environment. And this is to really understand if that data can also be used to further generate information around other discovery research, but also critically understand that the motivations for parents involved will be very different, and we need to think very carefully about how we engage and work with the parents of the babies going forward about how we use their data.    Vivienne: And the super exciting thing is we've started recruiting. How many mothers have we recruited?  Alice: So, we've recruited over 3,000 to date, and it's building every day and every week really. And it's really exciting because we see more and more trusts coming online and the study building and really starting to learn from the experience. And every week and every month, we're learning much more about how this process works, what the impact it's having, and kind of what we need to do over the coming few months and years to deliver it.    Vivienne: And we did a huge about of work at Genomics England before the study even started, to try and find out what people wanted. So, we found out, for instance, that people didn't want to know about late onset conditions, they did want to know about conditions where there was a treatment, and they wanted things that could be done for their babies in childhood. So, we had a really clear steer from the public about this project before we even started. So, how are we continuing to learn from the people who are involved in the study and the public? I mean Kerry, you've been involved in this aspect. We need to listen, don't we, to find out what's going on?    Kerry: We do, we do, and I think it's really encouraging to see the public dialogue and the amount of engagement work that was done there to kind of identify what some of those areas were, but it's really important that we don't stop that engagement there. It's really important to continue that, and I know that we've got quite a diverse group for our Patient and Public Involvement Advisory Group and the Evaluation Team, and one of the things they're really interested in is how we're going out there to speak with communities. You know, we can't just be reliant on the media, and press releases about the study. We need to actually go to communities and have these conversations so that people can have a conversation within an environment that they feel safe and confident with the people that they feel supported by as well.    So I think it's really key that we continue to ask those questions but also learning from the evaluation and, as we go through the process, of speaking to the patient organisations as well who support families that suffer from some conditions that we plan to identify through this study, and learn what some of their challenges are as well. You know, do they feel equipped to be able to support parents that are getting a diagnosis? As well as obviously their participants and the general public, to make sure that we're aware of attitudes and perceptions as the study goes along.    Vivienne: Because there's always a danger with this kind of study that it's people who are health literate who end up being involved. Whereas some of the people on whom the burden of rare disease is greatest may not either feel that they can access, or would want to access, this study. So, what are we doing there? How are we listening to people?  Kerry: When we are looking at recruitment as well, like you say, you know this is a research study and when we look at history and when we look at participants in research studies, we very rarely do you get a diverse representation of people in these types of studies. So, it's really important that those extra efforts are made really in terms of recruitment to get the right sample of people involved. And I know at Genomics England, that they have invested their time and money in terms of interpreters and translating materials and things, but actually it's the sites and recruiting people that need to be well resourced in order to use recruitment strategies, because if we're just looking at posters in waiting rooms, for instance, you're going to get a particular demographic of people that will respond to those kind of posters, such as people who don't speak English as a first language, it would be really difficult sometimes to read those kinds of posters and then to ask questions about that.     We need skilled people within sites that are recruiting who have got cultural competence who can have those conversations, address some of those areas, some of those concerns so that we can get that diverse representation.    Vivienne: So, there's a whole piece about equity of access for everybody and Dalia, perhaps you can explain why this is so important, scientifically as well as ethically? There's another piece about making sure that we get a full diversity represented.    Dalia: We know that some of the conditions are more common in certain populations or certain communities. We also know that some of the conditions are caused by certain variants in one population but not in the others. And these genetic causes even of the same condition can vary between different communities and different genetic ancestors.  On the other hand, our knowledge about the conditions and the genes, and the variants which cause them, come a lot from what we've seen before. Where we've seen those variants in the patients with the disease, and importantly where we've seen those variants in control populations where these individuals which don't have conditions.      Therefore, if we lack the diversity in our datasets, we would not know about all the diverse reasons of why conditions can be caused, or how it progresses, or what it might mean for individuals. And we would not be able to have equitable testing, or we wouldn't know whether the test works for everyone. If that happened, we might be in the territory where we can't detect or don't detect as well all the conditions across different individuals. But also, we may be having more false positive results and create more anxiety for families as well as burden for healthcare system.    Vivienne: So, are you saying, Dalia, that actually sometimes we might get a false positive, or indeed a false negative, simply because in that person, the condition which we think is usually caused by a particular change, they've got a slightly different change and so therefore we're not picking it up.  Dalia: Indeed, but it's one of the possibilities. If, let's say, all our knowledge about certain genes came from a limited number of individuals, seeing a new variant in another individual might seem that it's something really rare and never seen before and it's potentially changes how the gene functions, we would say; “oh that's maybe something which causes the disease,” when actually it can be that it is a benign variant, just a normal variation which is very common in another part of the world, it's just that we don't have enough data to know about it. So, we need to be aware of those risks and take it into account when we interpret the variants.      And, we also need to be transparent when operating in the environment. There was historical and investment in the diversity in research and our data sets still are not as diverse as we would like to be. It's shifting, the balance is definitely shifting in the last few years. A lot of effort is being done but the only way to shift the balance forever and make that genomic medicine work for everyone is to really actively engage those individuals and involve them in the research, and taking all the effort that Kerry was talking about.    Advert: The Genomics England Research Summit is fast approaching and registration is now open! Join us for this one day in-person event on Tuesday 17 June 2025. This year's agenda dives into rare condition diagnosis, cancer genomics, pharmacogenomics, therapeutic trials, and the impact of emerging technologies. Hear from leading experts and inspirational speakers as we explore the present and future of genomics and the latest research and technology from the Genomics England research community. Keep an eye on the website, genomicsresearchsummit.co.uk for all the details and to secure your spot. Spaces are limited, so don't miss out. We'll see you at the summit!  Vivienne: Alice, that goes back to this thing about holding the genomic data, because you need to hold the genomic data because the thing about genomics as always, you need to know what happens next. So, for instance, if somebody had a negative result and then later developed a condition, you need to be able to go back that data in order to find out what the problem was.  Kerry: That's right. You know, as Dalia talked about, we know that there is a risk within the study and we try and be clear about that in our participant information that there are some babies where they may have a genetic condition that we will need not find it, and others where we might find something that doesn't go on to be the actual condition. And we need to kind of monitor those in different ways.      So in particular in the cases where, if we've returned a result where we don't think we suspect a condition and a baby goes on to develop a condition, it's quite complex how we monitor that, and we're trying to go for a multi-track approach, and I think a lot of the benefits is some of the infrastructure that Genomic England already has that we can utilise.  So, some of the foundational things we've put into the study to help support the approach are things like the ability to contact parents regularly so we can actually work with them to find out over time if their babies develop conditions.    As you say, ability and consent to access the clinical data about the baby so that we can then access national data sets, and then we can then potentially monitor to see if babies seem to be showing signs of developing a condition. And also, really continuing to work with a network of clinical specialists where we've work quite hard over the last couple of years to build that kind of network and engage with them about the study, because they'll be the ones who the babies will come to if they develop those conditions. So, they are a really good route to us finding out, whether or not there are babies who have been part of the study who then go on to develop a condition.     And I think the reality is that this is a really complex process and it's something that even traditional screening programmes really struggle with, and that's why this multi-pronged approach is really important, and why also we see that this approach will evolve over time, and at the moment, the important thing is we've worked hard to put the right foundations in to allow us to do this type of monitoring, and to really evolve that approach as things develop and as more things come along potentially where we can invest in.    Vivienne: So, it's interesting, isn't it, because I guess that some parents would think that if you get a false positive or false negative, that it means that the test is at fault. And actually the accuracy of the test is good, but what we may have an issue with is that there is something else causing the problem that we don't yet know about. So, a big part of this project is giving much, much more information about the causes of conditions.    Alice: Yes, and I think that's also why the discovery research aspect is really important, the fact that we consent for that ability to hold the baby's data. So not only will we want to use it for the evaluation, but as I mentioned at the beginning, we have asked for parents to be able to allow us to link it to clinical data which then allows us to track over time and find out more information, because it's always the quality of the information we know that will help us in the future to identify these conditions, so the more we can generate potential information, you know, the more we will learn as a society.    And so it's actually quite an altruistic thing we're asking of parents, and that's something we recognise and that's why it's also important we think about, how we continue to engage with the parents and the baby over their lifetime to remind them that we're holding this data, but also to understand what their concerns and feelings are about us holding that data and how we're using it for that broader research.  Vivienne: And that's very much what you're involved in, isn't it Kerry?  Kerry: Yes, and I think sometimes in some ways that may offer some reassurance to parents as well, to know that's there as a reference point if things do develop over time, but I know that one of the things we're looking at as part of the evaluation, and the PPI Group we're involved in, is looking at the experiences of patients through this journey because actually it will create quite a lot of uncertainty.      As a parent of a child with a genetic condition, that uncertainty really is one of the hardest things to learn to live with. So at that early stage, one of the things we're looking at is that experience, how much support people have received, whether that has an impact on the parent and their child and their on bonding and their experiences and things like that, and I think it is important that we do that, but I think also having those references, where you're able to go back and ask those questions, that's really important that the support is in place, and that pathway really for parents to know where to go to. Because sometimes, although we may arrange to have calls at regular intervals and things, sometimes the questions of parents don't necessarily come at the time when they are having a telephone call. They come really late at night when there's nobody to pick up the phone, so having as much information as we can available, and those support structures in place, is really key.    Vivienne: We all start off these projects thinking that they are going to go in a particular way, but actually there's a lot of flexibility in this study, isn't there, Alice?  For instance, we will be looking at all those false positives, false negatives because we need to learn from that. We will be, perhaps, changing our approach as we go on if there is something that isn't working out. Is that what we're doing?  Alice: Yes, I think what we have recognise is it is a study and therefore that involves learning by it's very nature, and that's why partly we're working with external evaluation partners that Kerry's involved with, but also why we invest in a lot of things internally. Like we do a lot of user research with our midwives and our participants, and also potential participants. Because, actually we don't know the answer to this. No one's done this before, and so this is about all of us really learning, and learning in the right way and continuing to do that throughout the study, but also more importantly capturing that information and making sure that at the end of it, we then have some understanding of if we were to see that it's right to deliver this as a clinical service, what that might actually involve.      But also, even if we get to that point, I think beyond that we will still continue to learn over time and that's again why that long enduring consent is quite important, because we can then continue to maintain that long term evaluation and continue to maintain that long term potential to help further further research. And so that's the thing where actually we'll be learning for the next 10-15 years, really what the Generational Study has learnt, and actually what we have achieved through it.  Vivienne: I just want to move back to something that you mentioned, Kerry, about conditions that we're looking for, and there were a lot of very specific things. I've said that what parents wanted, but there's also some scientific things, and Dalia might want to come in here, that these are conditions that we pretty sure that if you've got the particular genetic change, that you will get the condition – something called penetrance. So, you know, we're not leaving people with a lot of uncertainty. But, how will we go about assessing new conditions as part of this study, or are we just on the ones that we're on at the moment?  Dalia: So, we started from the things we understand the best and we know how to detect them and we know how to confirm them because the tests that we are doing in Genomics England is a screening test, it will not be a definitive answer whether you have or you don't have a condition. Anyone which will get a positive result will be referred to an NHS specialist clinician for further assessment. And some of those positive results turn out not to have the conditions and some of them will have, and they will have their treatment pathways. So, we're started to very cautiously, and that's what came from public dialogue, everyone was saying that; “you need to be really cautious, we need to see that it works for the conditions that we understand well”.     But as a starting point, as we learn more, we're learning of how could we expand that list.  What would be acceptable for public. Maybe some conditions will have an experimental treatment, which currently would not be included in screening but as treatments evolve, at some stages maybe there will be opportunities to include some conditions in the future.      As our science evolves, we keep assessing the new conditions and seeing can we include them, would it be acceptable to parents, would it be acceptable to the healthcare system, and one of the things about screening it's really important not to cause harm. There are a lot of benefits in screening but if we didn't do it cautiously, it also has some risks, and we need to be very careful about it.    Vivienne: Now Kerry, there are lots of parent groups who will come along to us and say; “oh you must include this condition,” but perhaps there isn't yet a treatment, or there isn't a pathway in the NHS that will help people get what they need. And I guess if we try to include too many conditions, we would actually undermine trust.    Kerry: So, the patient organisation, our condition, Alström Syndrome, isn't included in the list. For our condition, there is no specific treatment although we do have a highly specialised service, and it is very important to get early diagnosis because children can develop heart failure and there are symptom-specific treatments available there. But I get the reasoning why there needs to be a specific treatment and the need to include just a smaller group at the beginning, but our hope as with I'm sure a lot of other patient organisations, is that our condition will be added at a later time if it is found that this is something that would be acceptable in routine care.    Advert: If you're enjoying what you've heard today and you'd like to hear some more great tales from the genomics coalface, why don't you join us on the Road to Genome podcast, where our host, Helen Bethell, chats to the professionals, experts and patients involved in genomics today. In our new series, Helen talks to a fantastic array of guests including the rapping consultant, clinical geneticist Professor Julian Barwell about Fragile X Syndrome, cancer genomics and the holistic approach to his practice. A genuine mic-drop of an interview. The Road to Genome is available wherever you get your podcasts.  Vivienne: Let me move on to another aspect of this study. These are babies, and we are holding their genomic information but at 16, they will be able to decide whether they want us to continue holding their genomic information. Alice, is that very much part of this programme to think about what we're going to say and how we're going to engage those 16-year-olds?  Alice: Yes, it very much is. What I always say, because I get asked this question a lot, is that I don't think we can pre-judge what that looks like. Because I look at my children, and certainly their lives are very different from my childhood, and I don't think we can imagine exactly what our babies will look in 16 years and what that world looks like. I think the important thing is many of things we are trying to do is that we lay the right foundations in place, and part of that is ensuring that we continue to think about how we engage with young people as the study evolves and over time, so that we understand what the world is looking like from their perspective.      But also, how do we equip the parents to talk about the fact that these babies are part of the study to them? What does that look like? How can we support them? And that's very much something we want to be looking at in the next year, really working with parents from the Generation Study to understand how best we can do that so that they can have some of that conversation for themselves as well. I think we can't pre-judge exactly how we need to talk about them and also not think it's just one thing. We need to evolve and work with the children as they grow up, and work with their parents to equip them because, as I said, we don't really know how they're going to access information in the future. You know certainly TikTok didn't exist when I was a child, and so that's what we've got to think about is what's the best avenues or forums to really engage properly with them as they grow.  Vivienne: Kerry, what other concerns to parents have that we're learning now?    Kerry: I think the concern is that when treatments are being developed, that they are not necessarily being developed for the whole population. They're often being developed for sub-sets of population because we don't have a complete dataset. And when you think about people being involved in research, people feel that they are being left behind because their data is not necessarily represented within there, it doesn't reflect their community, and it's not being discussed within communities, the different research opportunities and things have been available, I think it's the fact that we're not investing enough in community engagement and dialogue to explain more about genetics.   I think technology has advanced at pace. As a parent of a child with a genetic condition, that is very encouraging to see that, but I think sometimes the support and the information is not necessarily keeping up, so we're not having those open conversations really about genetics and genomics, and I think that's one of the things I hope that this study will really lead to, that it will now become much more part of everyday conversation.   Because often, when you have a child with a genetic condition, you first hear about a condition, the way you take in that information and ask questions is very different than having a conversation with the general public about genetics. When you're concerned that your child may have a condition or you may have a condition yourself, you're in a completely different mindset. So, the hope is that that dialogue will open so that people will be able to ask questions to learn more about the projects and things that are out there and available so that people are included and can take part in research if they want to. But it's important to remember that not everybody will want to. It's about being given informed choices and to do that we need to make sure that the support and the information is appropriate, inclusive and accessible.    Vivienne: We always have to remember, don't we, that if people say no to these things, it's not a failure to on our part, or a failure on their part. It's just something they've thought about and they don't want to do, and for all sorts of different reasons. And the other reflection I have about different communities is the ‘different' bit, is that what approach works for one community may not work for another, and I think that that's something that's going to have to evolve over length of the study, is finding the things that are the right way, the most helpful way to approach people.   Kerry: I completely agree. I think it's like you say, if people say no, that is completely their right to do so as long as they're saying no when they've been given the information to be able to really take that on board, think through, consider it and then make an informed decision. I think often people say no because they've not been given the right information to be able to understand what is expected, so they've not necessarily been given the opportunity. And I think we all want good outcomes for everybody. That doesn't mean delivering the services in the same way. Sometimes we need to deliver services in different ways because often services aren't very accessible for some communities to be able to access. So sometimes we need to make changes, adapt, to make sure that everybody has the same opportunities to the same outcomes.  Vivienne: We are constantly re-evaluating, rethinking, re-engaging to try and make it the best we can. Whether it's with different communities and different approaches. Whether it's with constantly assessing people who've had false positives, false negatives and finding out why that is the case. And in the future, I think this will have some really major effect.  Dalia, you're the scientist amongst us today. Tell us what you're hoping for from this study in science terms.  Dalia: So, first of all, we want to find the babies which we can treat before we develop symptoms, before we get ill, so that we can have more fulfilling lives. That's the bottom line. But we're doing that, we also will learn about the conditions. We'll learn a lot about the natural history of the conditions. What happens when you detect it before baby gets ill, then you start treatment, and how does it work in the diverse communities and diverse populations that we've talked about. Are there are any differences based on people's ancestry, but not just ancestry, about their lifestyle, about anything else which can affect how disease develops, or how the care or treatment goes.      So, that's kind of the bottom line. The top line and now our ultimate aim, probably many years from now, would be that we can detect variants of genes or conditions before they develop, and we can create treatments for them before our children get their conditions.  That's something that the science community is very excited about. I think we're quite a few years from that, but that's where we hope all this will be heading in the future.    Vivienne: It's really becoming a possibility, but the science is only the first part of it. It's the human interaction. It's the how it lands with people. It's how they feel about it. It's how they trust it. And these are all the things that we're really working on at Genomics England to make this study not just a scientific success, not just a success for the NHS, but also something that is really meaningful and important and valuable and trusted for people having babies. Would you agree?  Alice: Yes, 100%. I think, just to come in there, Viv, I think we've talked a bit about the importance of public trust and being the foundations of what we do, and I think that's something that Genomics England's always held true to itself, but I think for the purpose of the Generation Study, it's been one of kind of the foundational principles from the beginning, and I think Kerry and you have touched upon some really important themes today about how it's not a ‘one size fits all' approach. And I think very much that piece that we touched on a bit about, kind of, how do we make this accessible to everybody, we see it very much as not a ‘one size fits all', and so we've been trying lots of different things to really tackle that, and evolving the approaches which, as you said, that's where the flexibility comes in.      My hope for the next 12 months is that we can really, now that we've got the study up and running, work a lot with the some of the regional networks, the Genomic Medicine Service alliances who are working at the regional level, and the recruiting trusts, to really explore different approaches and work out how we can support them to engage with the communities in their areas, because they're the ones who will understand who they are, and our role is to really try and provide, as Kerry highlighted, the tools of support to allow them to do that, and to try and make sure that we can make this as equitable as possible in terms of people being able to at least understand the studies here, get the information in the appropriate way, and then as we have also talked about, making their own minds up about whether this is the right thing for them to be part of.    Vivienne: So, the final question for you all is if I'm a mother-to-be, where can I find out more information. Let's start with you, Kerry.  Kerry: Well, from the Generation Study website, there's information there. Midwives, GP practices, obviously they're often going to be your first port of call, so I'm hoping that they feel equipped to be able to answer those questions and to signpost people to one of the trusts that are involved.    Vivienne: And we've also got a Genomics 101 episode where we answer some of the frequently asked questions, and I think there are at least 2 or if not 3 separate episodes from Behind the Genes, which people can look for which look at different aspects of the project. Anything else, Alice, that we need to know?  Alice: So, Kerry highlighted it, the Generation Study website is a really good starting point, but that's a good place to also find out what trusts are involved because it's also important to know that this is not available in all trusts in England at the moment. We have a network and it's growing, and it is all around England, but the first place to start is, kind of, is it in your local trust?  And then from there, it's then engaging with your trust and hospitals where there will be information, and the midwives are prepared to kind of talk to people.  So those are, kind of, the good first places to start.    Vivienne: Well, we're going to wrap up there. It's been so good talking to you all. So, thank you to our guests Alice Tuff-Lacey, Kerry Leeson-Bevers, and Dalia Kasperaviciute for joining me as we talked through how the Generation Study is continuing to evolve as it responds to emerging challenges. Now, if you would like to hear more about this, then please subscribe to Behind the Genes on your favourite podcast app and, of course, we hope that you would like to rate this.  Because, if you rate it, it allows more people to see it and more people to get enthused about Behind the Genes, which we love. It's available through your normal podcast apps. I've been your host, Vivienne Parry. The podcast was edited by Bill Griffin at Ventoux Digital, and produced by Naimah Callachand at Genomics England. Thank you so much for listening. Bye for now.  

Guest: Dr Andrew Godfrey, Medical & Scientific Director of the Irish Blood Transfusion Service

At the 2025 National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to medicine—will be much discussed. In this curtain raiser, BioSpace speaks with conference chair Prathap Nagaraja Shastri of J&J about these highly anticipated topics. HostJef Akst, Managing Editor, BioSpaceGuestPrathap Nagaraja Shastri, Scientific Director and Group Leader, Clinical Pharmacology and Pharmacometrics, Johnson and JohnsonBioSpace is a media partner of the National Biotechnology Conference.

Join Rob Gorski, The Autism Dad, in a conversation with Dr. Pamela Feliciano, Scientific Director of SPARK for Autism. Dr. Feliciano, an autism mom herself, shares her personal journey and insights into SPARK's groundbreaking research. Discover how SPARK is connecting families with researchers to accelerate breakthroughs in autism understanding and support. Learn how you can get involved and contribute to this vital initiative. General Timeframes: Beginning of the episode: In the first 10 minutes, Dr. Feliciano shares her personal journey as an autism mom and discusses her son Dylan's progress. Mid-episode: Around the 20-minute mark, the conversation shifts to SPARK's mission and goals, exploring how the initiative is advancing autism research. Towards the end: In the final segment, you'll hear how families can get involved with SPARK and contribute to this important work. Links: SPARK for Autism: https://sparkforautism.org/ The Autism Dad Podcast: https://listen.theautismdad.com Special thanks to our sponsors: Safe Place Bedding: Sleep is a major challenge for many families in our community, and Safe Place Bedding can help. Their sensory-friendly, enclosed beds are perfect for kids with unique needs, and they make it easy to get permanent beds covered by insurance. Plus, their new travel bed ensures better sleep anywhere. Visit safeplacebedding.com/theautismdad to save 10% and give your child the gift of better sleep—because every family deserves a good night's rest. Autism 360: Autism 360 is a neuro-affirming app for parents of autistic children, offering 24/7 expert guidance, personalized plans, and practical support for daily challenges. Trusted by thousands, it provides affordable, real-time help. Use the code “theautismdad” to save 10% Mightier: Mightier helps kids self-regulate emotionally through biofeedback-based video games. Learn more and get a discount at Visit https://www.mightier.com/. Use code “theautismdad22” to save 10%. Call to Action: Visit SPARKforAutism.org today to learn more and join the movement! Subscribe to The Autism Dad Podcast on your favorite podcast listening app. For more information on The Autism Dad Podcast, to share feedback, to be a guest, or inquire about sponsorship opportunities, visit https://listen.theautismdad.com About the Host: Rob Gorski is The Autism Dad, a passionate advocate for autism awareness and acceptance. He shares his experiences and insights on his podcast and website. Connect with him by visiting https://theautismdad.com.

The Smart 7 is an award winning daily podcast that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 17 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:Guests Sian Taylor Philips - Director of Population Health at the University of WarwickKarin Smyth - Health Minister, UK Government Dr Liz O'Riordan - Cancer survivor, Author, Breast Cancer SurgeonProfessor Hashim Ahmed - Chair of Urology and Head of Speciality Surgery at Imperial College LondonWill Guyatt - The Smart 7's Tech Guru Donald Trump - 47th President of the United States of AmericaVolodomyr Zelensky - President of Ukraine Stuart Smith - Freelance Journalist Chris Stokel Walker - Journalist, Author, Lecturer Juliet Bouverie - CEO of the Stroke AssociationNicky Fox - Associate Administrator for NASA's Science Mission DIrectorate Shawn Domagal-Goldman - Research Scientist at NASA's Goddard Space Flight Centre Gabriel Vichera - Co-Founder and Scientific Director of the Biotech firm KhieronContact us over at X or visit www.thesmart7.comPresented by Ciara Revins, written by Liam Thompson and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

Struggling with eczema, psoriasis, muscle pain, wrinkles, or slow wound healing? Red light therapy is a powerful, non-invasive solution that supports faster recovery, reduces inflammation, and promotes skin health—all in the comfort of your home. In this episode, we uncover how this therapy works, why so many parents are turning to it, and how it can help both you and your children thrive. Dr. Genevieve Newton, the Scientific Director at Fringe, discusses the science behind red, blue, and near-infrared light, sharing research-backed benefits for everything from soothing sore muscles to speeding up healing after burns or injuries. Plus, we explore practical ways to use red light therapy for common pediatric concerns, helping you make informed choices for your family's health. If you're looking for safe, effective ways to support healing and wellness for your kids (and yourself!), this episode is for you. Topics Covered In This Episode: Red light therapy for pain relief Eczema and psoriasis relief How it supports brain health, including ADHD and Autism How it supports immune health Wound healing, skin health, and scar reduction What to look for in a device and what to avoid in popular devices Protocols for how to use it with your family Show Notes: Follow @fringeheals on Instagram Purchase a Fringe product and Get 15% off with promo code: DRMOM15  Get a 30-minute free training Fringe University Click here to learn more about Dr. Elana Roumell's Doctor Mom Membership, a membership designed for moms who want to be their child's number one health advocate! Click here to learn more about Steph Greunke, RD's Substack Mindset + Metabolism where women can learn how to nourish their bodies, hit their health and body composition goals, and become the most vibrant version of themselves.  Listen to today's episode on our website Dr. Genevieve Newton, DC, PhD  spent close to 20 years as a researcher and educator in the field of nutritional sciences before joining Fringe as its Scientific Director. Gen's job is to “bring the science” that supports Fringe's products and education. She is passionate about all things Fringe, and is a deep believer in healing body, mind and spirit using the gifts of the natural world.  This Episode's Sponsors  Our mission is a simple, but important one: To create products, content, and community centered around healing.  To do good things. We are the team at Fringe. We are a curious, passionate, outer-edge-living, nature-dwelling, music-loving, drum-beating group of fire-starting humans. We share stories about the powerful ways our ancestors healed, and provide solutions for utilizing their wisdom in our modern world.  We are passionate about connecting today's science to those powerful healing stories from our past. We dive into natural health topics and provide the science behind all the things your grandmother's grandmother did to heal – like making sure the cells in our body get the energy they need from the incredible power of light. Thanks for being a part of this journey with us.  INTRODUCE YOURSELF to Steph and Dr. Elana on Instagram. They can't wait to meet you! @stephgreunke @drelanaroumell Please remember that the views and ideas presented on this podcast are for informational purposes only.  All information presented on this podcast is for informational purposes and not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a healthcare provider. Consult with your healthcare provider before starting any diet, supplement regimen, or to determine the appropriateness of the information shared on this podcast, or if you have any questions regarding your treatment plan.

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, CEO of inGENEious RX Incorporated Pharmacogenomics Consulting, and Dr. Megan Landsverk, Scientific Director of MolDX® and Chief Science Officer of Palmetto GBA®, discuss how laboratories may overcome the challenges they face earning MolDX® coverage and reimbursement for their clinical pharmacogenomics tests. Specific to coverage determinations, the PGx veterans discuss test design, post-genotype translations, and technical assessments. Specific to reimbursement, the duo discusses evidence-based reporting and complete claim submissions. Also discussed is the importance of labs clearly defining intended use populations for tests and academic partnerships importance when labs develop and validate panels including drug-gene pairs the Clinical Pharmacogenetics Implementation Consortium and the United States Food and Drug Administration does not recognize as clinically utile for managing medications. Dr. Megan Landsverk is a Science Officer for Palmetto GBA, a Medicare Administrative Contractor (MAC) and a Science Director for the Molecular Diagnostic Services (MolDX) program developed to identify and establish coverage and reimbursement for molecular diagnostic services on behalf of Medicare. Dr. Landsverk received her PhD in Biochemistry and Molecular Biology from Baylor College of Medicine and postdoctoral training in Medical Genetics at the University of Washington. She is a board-certified Molecular Geneticist, completing her molecular genetics fellowship at Baylor College of Medicine. She has held multiple academic faculty positions and has numerous publications in the field of genetics. Prior to joining Palmetto, she served as a clinical laboratory director in academic, hospital, and commercial clinical laboratories and has experience in several genetic specialties including rare disease (pediatric and adult), cancer (somatic and inherited), and pharmacogenetics.

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, CEO of inGENEious RX Incorporated Pharmacogenomics Consulting, and Dr. Megan Landsverk, Scientific Director of MolDX® and Chief Science Officer of Palmetto GBA®, discuss how laboratories may overcome the challenges they face earning MolDX® coverage and reimbursement for their clinical pharmacogenomics tests. Specific to coverage determinations, the PGx veterans discuss test design, post-genotype translations, and technical assessments. Specific to reimbursement, the duo discusses evidence-based reporting and complete claim submissions. Also discussed is the importance of labs clearly defining intended use populations for tests and academic partnerships importance when labs develop and validate panels including drug-gene pairs the Clinical Pharmacogenetics Implementation Consortium and the United States Food and Drug Administration does not recognize as clinically utile for managing medications.  Dr. Megan Landsverk is a Science Officer for Palmetto GBA, a Medicare Administrative Contractor (MAC) and a Science Director for the Molecular Diagnostic Services (MolDX) program developed to identify and establish coverage and reimbursement for molecular diagnostic services on behalf of Medicare. Dr. Landsverk received her PhD in Biochemistry and Molecular Biology from Baylor College of Medicine and postdoctoral training in Medical Genetics at the University of Washington. She is a board-certified Molecular Geneticist, completing her molecular genetics fellowship at Baylor College of Medicine. She has held multiple academic faculty positions and has numerous publications in the field of genetics. Prior to joining Palmetto, she served as a clinical laboratory director in academic, hospital, and commercial clinical laboratories and has experience in several genetic specialties including rare disease (pediatric and adult), cancer (somatic and inherited), and pharmacogenetics.

How are happiness and success intertwined when it comes to business? What crucial element do you lose as a company when the boss or the culture becomes one of stress or pressure? Emma Seppälä teaches at the Yale School of Management and is a Scientific Director at the Center for Compassion and Altruism Research at Stanford University. She is also the author of several books, most recently Sovereign: Reclaim Your Freedom, Energy, and Power in a Time of Distraction, Uncertainty, and Chaos.Greg and Emma discuss the evolving field of happiness studies, its application in business, and Emma's research on the relationship between success, well-being, and stress. Emma shares insights on how high-stress cultures in academia and workplaces undermine long-term performance and creativity and offers practical strategies for individuals and leaders to cultivate emotional intelligence and resilience through practices like meditation and breathwork.*unSILOed Podcast is produced by University FM.*Show Links:Recommended Resources:Robert ThurmanSKY Breath MeditationBreathworkGuest Profile:EmmaSeppala.comFaculty Profile at Yale School of ManagementFaculty Profile at the Stanford Medicine Center for Compassion and Altruism Research and EducationSocial Profile on InstagramSocial Profile on FacebookSocial Profile on XLinkedIn ProfileHer Work:Amazon Author PageSovereign: Reclaim Your Freedom, Energy, and Power in a Time of Distraction, Uncertainty, and ChaosThe Happiness Track: How to Apply the Science of Happiness to Accelerate Your SuccessThe Oxford Handbook of Compassion ScienceYouTube ChannelEpisode Quotes:Self-awareness vs. self-criticism in leadership18:17: If you want to be a good leader, compassion is so essential. It's a no-brainer. And I teach a lot of female executives, male too, but I would say both of them are highly self-critical. I differentiate between self-awareness and self-criticism. Self-awareness is, oh, you know what? My statistics are terrible. Like I actually need to hire a statistician to help me on my team. That's self-awareness, right? Self-criticism is, I'm a terrible accountant. I can't do this. Like, I'm just so bad, all that stuff is either going to make you feel less than and all the consequences thereof or make you feel like you have to make up for it by being a jerk or "narcissist." Everyone's a narcissist these days, according to everybody else. You know what I mean? But, like, yeah, both of those are consequences of profound self-hatred. That's why, you know, self-awareness is key. Self-criticism? Not so much.Innovation starts with resilience and a sovereign state of mind11:24: What we need the most is innovation, both in our young people, in our employees, and all around ourselves. We need to figure out the problems in our lives, and the best way to access that is to come back to, I'm going to call it, a sovereign state because when you're sovereign and you're sort of centered within yourself, and you're in a calmer state, and you're less frazzled, and also the whole antifragile thing. Well, it's antifragile psychologically, so you're in a state where you are most resilient to the outside world and most creative.Why leadership begins with your well-being33:25: People can't flourish around you if you're stressed, if you're burnt out, if you're showing up yourself; it's not going to happen. As a leader, people are watching you. They're very attuned to you because they're watching out for their own safety, and they're measuring where they are at, where they stand, and so it's critical. I think that's a place where people get lost. You're like, "Oh, well, if I just offer these perks or see these things, everything will be fine." It's like, well, really, people see through you. They see through you. And if you're not authentic, they know that.

While GenAI has gotten all the attention, the capabilities of quantum computing are also bringing new experiences and capabilities to market. The University of Alberta, Alberta's Quantum City initiative, and Mphasis are working with global energy, transportation, and technology firms to find innovative new solutions. In this conversation, Joel Martin, Executive Research Leader at HFS Research, talks with Dr. Barry Sander, University of Calgary, Scientific Director of Quantum City, and Rohit Kumar Patel, AVP & Lead Data Science and QC at Mphasis. You will learn: Learn how a partnership to deliver quantum computing and quantum-as-a-service creates new value, innovation, and ecosystem partnerships

In this special edition of the podcast, we will talk with the new Editor-in-Chief Janet Rossant and hear about her vision for the journal, its promising future, and what she sees as some of the exciting prospects over the horizon for stem cell research. We will also talk with Yvonne Fisher, the journal's Managing Editor, and Jack Mosher of the ISSCR, about the evolution of the journal and its role in the Society. GuestsJanet Rossant is the new Editor-in-Chief of Stem Cell Reports. She holds an appointment as the Chief of Research Emeritus and Senior Scientist at The Hospital for Sick Children and is the President and Scientific Director of the Gairdner Foundation. Widely recognized as an expert in embryonic development, Professor Rossant has been recognized for her contributions to science with awards, including the Ross G. Harrison Medal (lifetime achievement award) from the International Society of Developmental Biologists, the March of Dimes Prize in Developmental Biology, the Conklin Medal from the Society for Developmental Biology, and the 2018 L'Oréal For Women in Science Award. She is a Fellow of the Royal Societies of both London and Canada, and an International member of the US National Academy of Sciences. She previously served as President of the ISSCR. Learn more about Stem Cell Reports editorial team. Yvonne Fisher is the Managing Editor of Stem Cell Reports. Yvonne received her PhD from Frankfurt University and did her postdoctoral work in the laboratory of Henrik Semb at the University of Lund in Sweden. Yvonne is the longest serving member of the journal, serving as Managing Editor since the journal's inception in 2012. Jack Mosher is the Scientific Advisor for the International Society for Stem Cell Research. He received his PhD from the University of North Carolina in Chapel Hill and was a postdoctoral fellow in the laboratory of Sean Morrison at the University of Michigan. Jack serves numerous roles for the Society including administrative oversight of Stem Cell Reports.  HostMartin Pera, Editor-in-Chief, Stem Cell Reports and The Jackson LaboratoryX: @martinperaJAXAbout Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians.X: @StemCellReportsAbout ISSCRWith nearly 5,000 members from more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health.ISSCR StaffKeith Alm, Chief Executive OfficerYvonne Fisher, Managing Editor, Stem Cell ReportsKym Kilbourne, Director of Media and Strategic CommunicationsMegan Koch, Marketing ManagerJack Mosher, Scientific AdvisorHunter Reed, Senior Marketing CoordinatorVoice WorkBen Snitkoff

Dr. Sealy Hambright owns and operates Hambright Consulting LLC. He holds Research Directorship positions at Restoration Biologics and Boston Children's Hospital. He is also a co-founder and Scientific Director of Base State Longevity in Aspen, CO. Connect with Sealy: https://www.instagram.com/sealyhambrightphd/ https://www.basestatelongevity.com/ Join the Peak Humans community: ⁠https://peakhumans.io/⁠ I would really appreciate it if you left a short review on Apple Podcasts/iTunes!  It takes only a minute and I love reading the reviews! Interested in sponsoring the podcast?  Email ⁠support@naeemmahmood.com⁠ Connect with Naeem: ⁠⁠https://www.instagram.com/iamnaeemmahmood/⁠⁠ Naeem is a world-renowned speaker and peak performance strategist in the areas of leadership, organizational behavior, psychology of achievement, and sales mastery, where he has advised some of the world's top organizations including SoFi, Northwestern Medicine, The US Army, Salesforce, and JP Morgan. Naeem was one of Tony Robbins' top national speakers where he delivered 1,000+ talks to over 50,000 people on the psychology of peak performance. Start your day right with AG1, packed with 75 high-quality ingredients that support gut health and overall performance. Get a FREE 1-year supply of Vitamin D and 5 free AG1 Travel Packs with your first purchase. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠drinkAG1.com/naeem⁠⁠⁠⁠⁠⁠

In this episode, André Loesekrug-Pietri, chairman of the Joint European Disruptive Initiative (JEDI), and General Jean-Paul Paloméros, former NATO Supreme Allied Commander Transformation, join host Tammy Haddad to discuss AI's transformative impact on science, deep tech, and Europe's key role. Loesekrug-Pietri highlights JEDI's upcoming AI Action Summit challenge on agricultural carbon storage, the need for sustainable AI innovation, and warns of the dangers of not engaging with China on AI. Paloméros shares his perspective on AI's role in defense and addresses the current complex global challenges.

Camila Rocha is the Scientific Director of CCI/Cebrap. A PhD in Political Science from the University of São Paulo, she won the USP Thesis Award and the best doctoral thesis award from the Brazilian Political Science Association. A finalist for the 64th Jabuti Prize with the book Less Marx, More Mises: Liberalism and the New Right in Brazil, she also serves as Global Advisor for Our Common Home (Geneva), is a member of the board of the Instituto Democracia em Xeque (Democracy in Check Institute – São Paulo), and a columnist for the daily newspaper Folha de São Paulo.Brazil is going through challenging times. There's never been a more important moment to understand Brazil's politics, society, and culture. To go beyond the headlines, and to ask questions that aren't easy to answer. 'Brazil Unfiltered,' does just that. This podcast is hosted by James N. Green, Professor of Brazilian History and Culture at Brown University and the National Co-Coordinator of the U.S. Network for Democracy in Brazil. Brazil Unfiltered is part of the Democracy Observatory, supported by the Washington Brazil Office. This podcast is edited and produced by Camilo Rocha in São Paulo.https://www.braziloffice.org/en/observatory#activities

Leon Kolankiewicz is Scientific Director of NumbersUSA and Vice-President of Scientists and Environmentalists for Population Stabilization. His career as a wildlife/fisheries biologist and environmental scientist spans more than 30 years, 40 states, and three countries.  He has worked for the U.S. Fish and Wildlife Service, Alaska Department of Environmental Conservation, Alaska Department Fish and Game, Orange County (California) […] Read full article: Episode 136: How To Save Greater Yellowstone From Runaway Sprawl

Learn more about INIM's Research Studies: https://www.nova.edu/nim/research-studies/index.html  Haylie Pomroy welcomes back Jamie Seltzer, the Scientific Director of MEAction for another insightful conversation about myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). They explore how personalized nutrition, pacing, and lifestyle adjustments can support the management of chronic conditions, including post-exertional malaise (PEM), long COVID, and postural orthostatic tachycardia syndrome (POTS). Jamie offers practical tips on preparing simple, healthy meals, understanding the stages of illness, and creating a less stressful environment. Together, they emphasize how small changes can significantly improve quality of life.  Whether you're living with ME/CFS, caring for someone who is, or looking to learn more about chronic illness, this episode provides valuable advice and insights. Tune in to the Hope and Help for Fatigue and Chronic Illness – How To Manage ME/CFS and Other Chronic Illnesses with Jaime Seltzer. If you are interested in joining a Gulf War Illness (GWI) trial, please complete the Recruitment Registry Form. https://redcap.nova.edu/redcap/surveys/?s=Y9YF8JJWJRK8HEKL%20&_gl=1*1fipp18*_gcl_aw*R0NMLjE3MDc5MTgwMzIuRUFJYUlRb2JDaE1JeWNyUXVfcXFoQU1WU1pCYUJSM3AyQWRBRUFBWUFTQUFFZ0s1NWZEX0J3RQ..*_gcl_au*MTg2NjgwMDQ4Ni4xNzA3MTQwNzgx  Sign up for the COVID-UPP Study: https://redcap.nova.edu/redcap/surveys/?s=RMEDJ7LKCX&_gl=1*1h830h7*_gcl_au*MTM2NDA0MTQyOS4xNzE1MDA0ODAy Jaime Seltzer is the Scientific Director at MEAction, a nonprofit advocating for those with chronic illnesses. She bridges communication between healthcare, government, and research sectors, representing ME Action globally. Additionally, Jaime collaborates with institutions like Stanford Medicine and Mayo Clinic Rochester on post-infectious chronic diseases research. She brings personal insight to her work as someone living with ME/CFS.  LinkedIn: https://www.linkedin.com/in/jaime-seltzer-b23abb14/ Twitter: https://twitter.com/exceedhergrasp1 https://twitter.com/meactnet Website: https://www.meaction.net/ Facebook: https://www.facebook.com/MEActNet/ Instagram: https://www.facebook.com/meactnet Subscribe to the MEAction Newsletter: https://www.meaction.net/subscribe/ Donate to the MEAction Network: meaction.net/donate Neuroinflammation Research Review (2019) by Jaime Seltzer: http://www.meaction.net/wp-content/uploads/2019/06/19_MEA_Revised_2019_Research_Summary_190610.pdf Pacing and Management Guides: https://www.meaction.net/resource/pacing-and-management-guide/  Ask Mayo Expert: https://www.meaction.net/2023/04/26/mecfs-algorithm-is-live/ -----------------------------  Enjoy our show? Please leave us a 5-star review so we can bring hope and help to others.  Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d This podcast is brought to you by the Institute for Neuro-Immune Medicine. Learn more about us here.   Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM #MECFS #PEM #LongCOVID #ChronicFatigue #MyalgicEncephalomyelitis #ChronicIllness #Healthcare #ChronicIllnessCare #PostExertionalMalaise #POTS #PEM #ChronicFatigueManagement #HealthPodcast 

Learn more about INIM's Research Studies: https://www.nova.edu/nim/research-studies/index.html   Haylie Pomroy welcomes back Jamie Seltzer, the Scientific Director of MEAction for another insightful conversation about myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).   They explore how personalized nutrition, pacing, and lifestyle adjustments can support the management of chronic conditions, including post-exertional malaise (PEM), long COVID, and postural orthostatic tachycardia syndrome (POTS). Jamie offers practical tips on preparing simple, healthy meals, understanding the stages of illness, and creating a less stressful environment. Together, they emphasize how small changes can significantly improve quality of life.   Whether you're living with ME/CFS, caring for someone who is, or looking to learn more about chronic illness, this episode provides valuable advice and insights.   Tune in to the Hope and Help for Fatigue and Chronic Illness – How To Manage ME/CFS and Other Chronic Illnesses with Jaime Seltzer.   If you are interested in joining a Gulf War Illness (GWI) trial, please complete the Recruitment Registry Form. https://redcap.nova.edu/redcap/surveys/?s=Y9YF8JJWJRK8HEKL%20&_gl=1*1fipp18*_gcl_aw*R0NMLjE3MDc5MTgwMzIuRUFJYUlRb2JDaE1JeWNyUXVfcXFoQU1WU1pCYUJSM3AyQWRBRUFBWUFTQUFFZ0s1NWZEX0J3RQ..*_gcl_au*MTg2NjgwMDQ4Ni4xNzA3MTQwNzgx   Sign up for the COVID-UPP Study: https://redcap.nova.edu/redcap/surveys/?s=RMEDJ7LKCX&_gl=1*1h830h7*_gcl_au*MTM2NDA0MTQyOS4xNzE1MDA0ODAy   Jaime Seltzer is the Scientific Director at MEAction, a nonprofit advocating for those with chronic illnesses. She bridges communication between healthcare, government, and research sectors, representing ME Action globally. Additionally, Jaime collaborates with institutions like Stanford Medicine and Mayo Clinic Rochester on post-infectious chronic diseases research. She brings personal insight to her work as someone living with ME/CFS.    LinkedIn: https://www.linkedin.com/in/jaime-seltzer-b23abb14/ Twitter: https://twitter.com/exceedhergrasp1 https://twitter.com/meactnet Website: https://www.meaction.net/ Facebook: https://www.facebook.com/MEActNet/ Instagram: https://www.facebook.com/meactnet   Subscribe to the MEAction Newsletter: https://www.meaction.net/subscribe/   Donate to the MEAction Network: meaction.net/donate Neuroinflammation Research Review (2019) by Jaime Seltzer: http://www.meaction.net/wp-content/uploads/2019/06/19_MEA_Revised_2019_Research_Summary_190610.pdf   Pacing and Management Guides: https://www.meaction.net/resource/pacing-and-management-guide/   Ask Mayo Expert: https://www.meaction.net/2023/04/26/mecfs-algorithm-is-live/   -------------------------------------------------------------------------------------------------   Enjoy our show? Please leave us a 5-star review so we can bring hope and help to others.   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d   This podcast is brought to you by the Institute for Neuro-Immune Medicine. Learn more about us here.    Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM #MECFS #PEM #LongCOVID #ChronicFatigue #MyalgicEncephalomyelitis #ChronicIllness #Healthcare #ChronicIllnessCare #PostExertionalMalaise #POTS #PEM #ChronicFatigueManagement #HealthPodcast 

Camila Rocha is the Scientific Director of CCI/Cebrap. A PhD in Political Science from the University of São Paulo, she won the USP Thesis Award and the best doctoral thesis award from the Brazilian Political Science Association. A finalist for the 64th Jabuti Prize with the book Less Marx, More Mises: Liberalism and the New Right in Brazil, she also serves as Global Advisor for Our Common Home (Geneva), is a member of the board of the Instituto Democracia em Xeque (Democracy in Check Institute – São Paulo), and a columnist for the daily newspaper Folha de São Paulo.Brazil is going through challenging times. There's never been a more important moment to understand Brazil's politics, society, and culture. To go beyond the headlines, and to ask questions that aren't easy to answer. 'Brazil Unfiltered,' does just that. This podcast is hosted by James N. Green, Professor of Brazilian History and Culture at Brown University and the National Co-Coordinator of the U.S. Network for Democracy in Brazil.Brazil Unfiltered is part of the Democracy Observatory, supported by the Washington Brazil Office. This podcast is edited and produced by Camilo Rocha in São Paulo.https://www.braziloffice.org/en/observatory#activities

In this special episode of Restorative Works!, host Claire de Mezerville López welcomes Leah Koumentaki, Ph.D., and is joined by co-host Federico Reggio, Ph. D., from the European Forum for Restorative Justice (EFRJ), to celebrate Restorative Justice Week. This episode is part of a special series, "Restorative Justice in Local Communities Around the World," created in partnership with the EFRJ. Join us as we explore Dr. Koumentaki's research and the unique and enduring restorative justice practice known as "Sasmos."  Dr. Koumentaki delves into the heart of this vernacular restorative process, revealing how it continues to serve as a community-driven alternative to the Greek judicial system. Through the lens of Cretan cultural values like solidarity, respect, and belonging, Sasmos offers a powerful model for addressing harm and wrongdoing, while prioritizing reconciliation and the reintegration of individuals into their communities. Dr. Koumentaki's decolonial and critical approach to research challenges traditional Eurocentric frameworks and emphasizes the importance of ethnography in restorative justice practices. By weaving together tradition and innovation, Dr. Koumentaki's work offers valuable insights into how ancient justice systems can inform modern restorative practices. Dr. Koumentaki successfully completed her doctoral studies in Criminology at the University of Essex in 2022. She conducted the first comprehensive and systematic research on the Cretan Sasmos, which she concluded is a vernacular restorative justice process. Dr. Koumentaki's work highlights how Sasmos is closely related to the tradition of justice in Crete while, until today, is employed into highland communities of the island, predominately in lieu of the operation of the Greek judicial authorities. Prior to her doctoral studies, Dr. Koumentaki co-ordinated research projects on restorative justice and other topics related to criminology. During her doctoral research she was involved in teaching as an assistant lecturer in Criminology and Sociology, both at University of Essex and Royal Holloway University of London. She currently works as a lecturer in Criminology at University of Keele. Her research interests focus on social harm, criminality, punishment and justice from a decolonial, critical, and zymological strand of view. Dr. Reggio is an associate professor of philosophy of law and public ethics at the University of Padova. He serves as Senior Researcher at the University of Padua, Professor of Philosophy of Law, and Scientific Director of the Winter School Transforming 21st Century Conflicts. He chairs the Scientific Committee of the EFRJ and is the Scientific Director of the Mediares Journal. Tune in to learn more about Sasmos, the future of restorative justice, and the importance of preserving indigenous knowledge and traditions in our pursuit of fairness and equity.

Today on the Egg Whisperer Show, I'm excited to be joined by Dr. Nabil Arrach. Dr. Arrach is the Scientific Director at Progenesis, Inc. He has 20 years of research experience in molecular genetics, both in preclinical and clinical settings. He was the first scientist to optimize and validate next generation sequencing for PGT-A and PGT-M and he continues to work on new emerging fields in IVF. We will be talking about who should be testing their embryos, the difference between chromosomes and genes, mosaicism, and the importance and limitations of genetic testing. Read the full show notes on Dr. Aimee's website Find out more about Progenesis at their website. Do you have questions about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, November 18, 2024 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom.   Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Dr. Meritxell Huch is a Scientific Director at the Max Planck Institute of Molecular Cell Biology and Genetics and an Honorary Professor at the Technical University of Dresden. Her research focuses on liver and pancreas organoid models.  She discusses a protocol for liver mesenchyme and ductal cell organoid co-culture and generating bipotent stem cells from the liver. She also tells her story of moving throughout Europe to pursue her scientific passions.

Red Light Therapy is a powerful tool that's been gaining traction in recent years, and for good reason. It can actually improve mitochondrial function. But  how can it benefit our children, specifically those with ADHD? Find out  in this episode of the Soaring Child podcast.  Dr. Genevieve Newton, DC, PhD  spent close to 20 years as a researcher and educator in the field of nutritional sciences before joining Fringe as its Scientific Director. Dr. Newton's job is to “bring the science” that supports Fringe's products and education. She is passionate about all things Fringe, and is a deep believer in healing the body, mind and spirit using the gifts of the natural world. Tune in to this episode to learn more about red light therapy and its benefits for kids with ADHD.  Links Mentioned in the Show:  Book a free call with our team - http://adhdthriveinstitute.com/meet  Find Red Light Therapy Products Online (use code DANA15 for 15% off any red light product) - https://fringeheals.com/ref/95/ Key Takeaways: [2:50] What is red light therapy? [4:30] How red light therapy works [9:17] How oxidative stress affects mitochondria [12:30] Ways red light therapy benefits kids with ADHD [20:51] How can parents use right light therapy with their kids [28:45] Recommended time kids should use red light therapy daily [30:34] Is red light therapy safe? Memorable Moments: "Red light therapy is “a very popular topic right now, but there's a lot of misunderstanding about it.” ”We need to start off by talking about what sunlight actually is.” ”Red light therapy specifically would be the application of red, near infrared or both red and near infrared light for the purpose of influencing biology.” ”Red light therapy is going to work on us on a cellular level.” ”We have major problems with mitochondrial function. And so when you look at the literature for kids with ADHD, adolescents, adults, it's pretty clear at this point that mitochondrial dysfunction is associated with the pathology of ADHD. So in theory, something like red light therapy that comes in and helps to support that mitochondrial function could be expected to have a positive effect on the condition.” ”We have this horrible situation that so many people are unaware of and participating in without even knowing it whereby we are exposing our kids to bright lights at night...The exposure to the bright light at night and the blue light shifts that circadian rhythm by about 2 hours.” ”20 minutes for head, 20 minutes for gut, that's an ideal length of time...Once a day is perfect. But you can also see benefits in literature of 3X a week, 4X a week, 5X a week, 7X a week…I would recommend anywhere from 3-7. What we don't recommend is doubling up and doing the same body part twice in one day.” How to Connect with Dr. Genevieve Newton Website - https://fringeheals.com/ref/95/  (use code DANA15 for 15% off any red light product)  Instagram - https://www.instagram.com/fringeheals/  Dana Kay Resources:

Zack Varkaris is the Scientific Director and founder of Austin Biotec. He holds a BSc in Marine and Molecular biology from Heriot Watt University. In 2011, he developed an algae to biofuel system, which produced an unexpected byproduct of anti-ageing compounds. Whilst researching the effectiveness of these molecules he created anti-ageing topical creams, progressing into stem cell rejuvenation.   Working by the Ethos: A fully functional reproductive system and aesthetic maintenance is the foundation for a completely extended life resulted in the creation of the Rejucvacyte™️ procedure to maximize Human Health and lifespan.  Schedule a consult https://www.austinbiotec.com/ Use code ZORA for a special offer on Kalahari Gold marula oil https://kalaharigold.com/ Contact Zack Varkaris: Website: https://www.austinbiotec.com/ Instagram: @zackvarkaris Instagram: @austinbiotec Facebook: Austin Biotec Email: Info@austinbiotec.com Get Primeadine by Oxford Healthspan. 15% discount with code ZORA ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here. Get Mitopure by Timeline. 10% discount with code ZORA at timeline.com/zora Join ⁠⁠⁠Biohacking Menopause⁠⁠⁠ before November 1, 2024 to win a bottle of Oxford Healthspan's Primeadine spermidine valued at ($90). 15% off with code ZORA here. Join the Hack My Age community on: Facebook Page : ⁠⁠⁠⁠⁠@⁠Hack My Age⁠ Facebook Group: ⁠⁠⁠⁠⁠⁠@⁠Biohacking Menopause⁠⁠⁠⁠⁠⁠ ⁠ Instagram: ⁠⁠⁠⁠⁠@⁠HackMyAge⁠ Website: ⁠⁠⁠⁠⁠⁠HackMyAge.com⁠ ⁠Biohacking Menopause⁠ membership group Email: zora@hackmyage.com This podcast is edited by ⁠⁠⁠⁠⁠jonathanjk@gmail.com We covered: -   What it means to rejuvenate the ovaries -   How women can live longer better with their own production of hormones -   What are the probabilities of actually having a baby in your 50s -   Who can qualify and who doesn't for the Rejuvacyte procedure -   The cost and steps of skipping the HRT and creating your own estrogen. --- Support this podcast: https://podcasters.spotify.com/pod/show/hackmyage/support

How can the 15-minute city model revolutionize urban living, enhance wellbeing, and reduce our carbon footprint? Online shopping is turning cities into ghost towns. We can now buy anything anywhere anytime. How can we learn to stop scrolling and start strolling and create more livable, sustainable communities we are happy to call home.Carlos Moreno was born in Colombia in 1959 and moved to France at the age of 20. He is known for his influential "15-Minute City" concept, embraced by Paris Mayor Anne Hidalgo and leading cities around the world. Scientific Director of the "Entrepreneurship - Territory - Innovation" Chair at the Paris Sorbonne Business School, he is an international expert of the Human Smart City, and a Knight of the French Legion of Honour. He is recipient of the Obel Award and the UN-Habitat Scroll of Honour. His latest book is The 15-Minute City: A Solution to Saving Our Time and Our Planet.“It all starts at home. As a university professor, I have observed the process of transformation of different generations. We need to find a sense of life. We need to find a sense of belonging to our humanity, but to have this sense of life, we need to find a sense in our local communities.”https://www.moreno-web.net/https://www.wiley.com/en-us/The+15-Minute+City%3A+A+Solution+to+Saving+Our+Time+and+Our+Planet-p-9781394228140www.creativeprocess.infowww.oneplanetpodcast.orgIG www.instagram.com/creativeprocesspodcast

“It all starts at home. As a university professor, I have observed the process of transformation of different generations. We need to find a sense of life. We need to find a sense of belonging to our humanity, but to have this sense of life, we need to find a sense in our local communities.”Carlos Moreno was born in Colombia in 1959 and moved to France at the age of 20. He is known for his influential "15-Minute City" concept, embraced by Paris Mayor Anne Hidalgo and leading cities around the world. Scientific Director of the "Entrepreneurship - Territory - Innovation" Chair at the Paris Sorbonne Business School, he is an international expert of the Human Smart City, and a Knight of the French Legion of Honour. He is recipient of the Obel Award and the UN-Habitat Scroll of Honour. His latest book is The 15-Minute City: A Solution to Saving Our Time and Our Planet.https://www.moreno-web.net/https://www.wiley.com/en-us/The+15-Minute+City%3A+A+Solution+to+Saving+Our+Time+and+Our+Planet-p-9781394228140www.creativeprocess.infowww.oneplanetpodcast.orgIG www.instagram.com/creativeprocesspodcast

How can the 15-minute city model revolutionize urban living, enhance wellbeing, and reduce our carbon footprint? Online shopping is turning cities into ghost towns. We can now buy anything anywhere anytime. How can we learn to stop scrolling and start strolling and create more livable, sustainable communities we are happy to call home.Carlos Moreno was born in Colombia in 1959 and moved to France at the age of 20. He is known for his influential "15-Minute City" concept, embraced by Paris Mayor Anne Hidalgo and leading cities around the world. Scientific Director of the "Entrepreneurship - Territory - Innovation" Chair at the Paris Sorbonne Business School, he is an international expert of the Human Smart City, and a Knight of the French Legion of Honour. He is recipient of the Obel Award and the UN-Habitat Scroll of Honour. His latest book is The 15-Minute City: A Solution to Saving Our Time and Our Planet.“It all starts at home. As a university professor, I have observed the process of transformation of different generations. We need to find a sense of life. We need to find a sense of belonging to our humanity, but to have this sense of life, we need to find a sense in our local communities.”https://www.moreno-web.net/https://www.wiley.com/en-us/The+15-Minute+City%3A+A+Solution+to+Saving+Our+Time+and+Our+Planet-p-9781394228140www.creativeprocess.infowww.oneplanetpodcast.orgIG www.instagram.com/creativeprocesspodcast

“It all starts at home. As a university professor, I have observed the process of transformation of different generations. We need to find a sense of life. We need to find a sense of belonging to our humanity, but to have this sense of life, we need to find a sense in our local communities.”Carlos Moreno was born in Colombia in 1959 and moved to France at the age of 20. He is known for his influential "15-Minute City" concept, embraced by Paris Mayor Anne Hidalgo and leading cities around the world. Scientific Director of the "Entrepreneurship - Territory - Innovation" Chair at the Paris Sorbonne Business School, he is an international expert of the Human Smart City, and a Knight of the French Legion of Honour. He is recipient of the Obel Award and the UN-Habitat Scroll of Honour. His latest book is The 15-Minute City: A Solution to Saving Our Time and Our Planet.https://www.moreno-web.net/https://www.wiley.com/en-us/The+15-Minute+City%3A+A+Solution+to+Saving+Our+Time+and+Our+Planet-p-9781394228140www.creativeprocess.infowww.oneplanetpodcast.orgIG www.instagram.com/creativeprocesspodcast

“It all starts at home. As a university professor, I have observed the process of transformation of different generations. We need to find a sense of life. We need to find a sense of belonging to our humanity, but to have this sense of life, we need to find a sense in our local communities.”Carlos Moreno was born in Colombia in 1959 and moved to France at the age of 20. He is known for his influential "15-Minute City" concept, embraced by Paris Mayor Anne Hidalgo and leading cities around the world. Scientific Director of the "Entrepreneurship - Territory - Innovation" Chair at the Paris Sorbonne Business School, he is an international expert of the Human Smart City, and a Knight of the French Legion of Honour. He is recipient of the Obel Award and the UN-Habitat Scroll of Honour. His latest book is The 15-Minute City: A Solution to Saving Our Time and Our Planet.https://www.moreno-web.net/https://www.wiley.com/en-us/The+15-Minute+City%3A+A+Solution+to+Saving+Our+Time+and+Our+Planet-p-9781394228140www.creativeprocess.infowww.oneplanetpodcast.orgIG www.instagram.com/creativeprocesspodcast

How can the 15-minute city model revolutionize urban living, enhance wellbeing, and reduce our carbon footprint? Online shopping is turning cities into ghost towns. We can now buy anything anywhere anytime. How can we learn to stop scrolling and start strolling and create more livable, sustainable communities we are happy to call home.Carlos Moreno was born in Colombia in 1959 and moved to France at the age of 20. He is known for his influential "15-Minute City" concept, embraced by Paris Mayor Anne Hidalgo and leading cities around the world. Scientific Director of the "Entrepreneurship - Territory - Innovation" Chair at the Paris Sorbonne Business School, he is an international expert of the Human Smart City, and a Knight of the French Legion of Honour. He is recipient of the Obel Award and the UN-Habitat Scroll of Honour. His latest book is The 15-Minute City: A Solution to Saving Our Time and Our Planet.“It all starts at home. As a university professor, I have observed the process of transformation of different generations. We need to find a sense of life. We need to find a sense of belonging to our humanity, but to have this sense of life, we need to find a sense in our local communities.”https://www.moreno-web.net/https://www.wiley.com/en-us/The+15-Minute+City%3A+A+Solution+to+Saving+Our+Time+and+Our+Planet-p-9781394228140www.creativeprocess.infowww.oneplanetpodcast.orgIG www.instagram.com/creativeprocesspodcast

“It all starts at home. As a university professor, I have observed the process of transformation of different generations. We need to find a sense of life. We need to find a sense of belonging to our humanity, but to have this sense of life, we need to find a sense in our local communities.”Carlos Moreno was born in Colombia in 1959 and moved to France at the age of 20. He is known for his influential "15-Minute City" concept, embraced by Paris Mayor Anne Hidalgo and leading cities around the world. Scientific Director of the "Entrepreneurship - Territory - Innovation" Chair at the Paris Sorbonne Business School, he is an international expert of the Human Smart City, and a Knight of the French Legion of Honour. He is recipient of the Obel Award and the UN-Habitat Scroll of Honour. His latest book is The 15-Minute City: A Solution to Saving Our Time and Our Planet.https://www.moreno-web.net/https://www.wiley.com/en-us/The+15-Minute+City%3A+A+Solution+to+Saving+Our+Time+and+Our+Planet-p-9781394228140www.creativeprocess.infowww.oneplanetpodcast.orgIG www.instagram.com/creativeprocesspodcast

Episode 88. Eugene Yeo is a Professor at UC San Diego and is building a scientific ecosystem in San Diego. He runs the Innovation Center at Sanford Stem Cell Institute, is Scientific Director at the Sanford Consortium, Chief Scientist at the Sanford labs for Innovative Medicines, and Director of UC San Diego's Center for RNA Technologies and Therapeutics.

Those who watch the long running reality dating show franchise, ABC's The Bachelor, know that the women on it go the distance for a chance at love; and former contestant Clare Crawley is no exception. Clare is best known as the Runner Up in Season 16 of the series, leading to her role as ABC's Bachelorette in Season 18. She also appeared on Bachelor in Paradise twice and Winter Games, making her one of the most recognizable cast members in The Bachelor franchise. But in recent years, Clare has been known for something else – making headlines because of her fertility struggles.She first came out with her vulnerable fertility story via Instagram, when she was finally expecting via gestational surrogacy by sharing, “I can tell you how hard it has been to hold the secret as I've shared the last 10 years of my life with you all. This is one journey, though, that Ryan and I have been keeping close to our hearts as we navigated the uncertain world of IVF and all that comes with it….” Clare concluded the post by thanking her fertility specialist, Dr. Aimee “The Egg Whisperer” for ‘helping miracles happen'.Clare's doctor, Dr. Aimee Eyvazzadeh, joins our episode midroll to share more about how she worked with Clare and with other patients in her practice, many of whom are over 40 years old, and why she puts all of her patients on the clinically proven NAD plus boosting supplement, Tru Niagen.Tru Niagen, the episode sponsor, was developed by ChromaDex, and their Scientific Director, Mona Rosene also joins the episode midroll break to share more on the scientific standards of Tru Niagen and why people navigating reproductive journeys and who want to support healthy aging may want to consider taking the supplement. Pregnantish listeners! If you want to try Tru Niagen, use EGGCELLS20 for 20% off at truniagen.com Hosted on Acast. See acast.com/privacy for more information.

Dr. Rob Verkerk is an internationally acclaimed scientist with over 25 years' experience in the field of agricultural and healthcare sustainability. He's Founder and Executive & Scientific Director of the Alliance for Natural Health. He provides a deep dive on the importance of natural health solutions and shares insights on the ongoing battle against regulatory challenges and censorship. Dr. Verkerk emphasizes the role of ANH in protecting access to natural therapies and highlights the significant advancements and regulatory threats pertaining to homeopathy, peptides, dietary supplements, bioidentical hormones, CBD and NMN. Furthermore, he details breakthroughs in anti-aging. Will RFK Jr.'s platforming of natural health care in the Presidential campaign make a difference? How COVID missteps have created public disenchantment with mainstream health authorities. How government and social media censorship has throttled down access to truthful information about natural alternatives. Legal initiatives to push back on the regulatory state. Overcoming looming challenges to the natural supplement industry. He also delves into the implications of the recent Supreme Court decision overturning Chevron deference, positioning it as an opportunity to challenge restrictive regulatory practices. Finally, he touches on the necessity of connecting with nature and the role of political movements in reshaping the American healthcare landscape.

Dr. Hoffman continues his conversation with Dr. Rob Verkerk, Founder, Executive & Scientific Director of the Alliance for Natural Health International & Alliance for Natural Health USA.